только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 11 / 21
Страница 3 / 27

Список литературы

70. Zhang Y. et al. Sleep in Parkinson’s disease: A systematic review and meta- analysis of polysomnographic findings // Sleep Med. Rev. 2020. Vol. 51. P. 101281.

71. Broen M.P.G. et al. Prevalence of anxiety in Parkinson’s disease: A systematic review and meta‐analysis // Mov. Disord. 2016. Vol. 31, № 8. P. 1125–1133.

72. Reijnders J.S.A.M. et al. A systematic review of prevalence studies of depression in Parkinson’s disease // Mov. Disord. 2008. Vol. 23, № 2. P. 183–189.

73. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018; 33:1248.

74. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease N Engl J Med 1989; 321: 1364–1371.

75. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520–525.

76. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937–1943.

77. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561–566.

78. Olanow CW, Rascol O, Hauser R, et al. A double blind, delayed-start trial of rasagiline in Parkinson’sdisease. N Engl J Med 2009; 361: 1268–1278.

79. Oertel WH et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study. Movement Disorders 2006; 21.-№3: 343-353.

80. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–1661.

81. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five- year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–1491.

82. Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101

83. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006; 21: 343–353.

84. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. The Parkinson Study Group. N Engl J Med 2004; 351: 2498–2508.

85. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2:73.

86. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20:342.

87. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001; 8: 95–100.

88. Jankovic J, Hunter C. A double-blind, placebo -controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 271–276.

89. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. The Parkinson Study Group. Arch Neurol 2002; 59: 1541–1550.

90. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. The ICV GDNF Study Group. Neurology 2003; 60: 69–73.

91. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931–1938.

92. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25: 858–866.

93. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. PKDS009 Study Group. CNS Drugs 2004; 18: 733–746.

94. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863–868.

95. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32: 475–488.Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399–406.

96. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–580.

97. Leentjens AF The role of Dopamine Agonists with Parkinson’s disease. Drugs 2011; 71.-№3: 273-286.

98. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179–1183.

99. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 2007; 6: 826–829.

100. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71:474.

101. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66:563.